Fri, Dec 26, 2014, 9:24 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Cyclacel Pharmaceuticals, Inc. (CYCC) Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • stockangel1@ymail.com stockangel1 Jan 22, 2013 6:53 PM Flag

    WoW that's all I can say ADXS about to help cure / treat cervical cancer! Phase 2 Trials in process!

    Thomas Moore, Advaxis’ Chairman and Chief Executive Officer, stated, “We are delighted to welcome Dan O’Connor to Advaxis. Now that our clinical development has reached an advanced stage, his success as a general counsel and in leading business development and licensing negotiations is a timely addition to our management team. We are very fortunate to attract a highly experienced professional of this caliber. It is a significant endorsement of Advaxis’ immunotherapy technology and our potential to unlock unrealized enterprise value.”

    Mr. O’Connor, age 48, has fifteen years of executive, legal, and regulatory experience in the biopharmaceutical industry with ImClone Systems, PharmaNet and Bracco Diagnostics.

    "I believe that Advaxis’ future holds tremendous potential," said Mr. O’Connor. "I look forward to continuing the company's culture of decisiveness and efficient execution. We will aggressively advance ADXS-HPV and our other pipeline product candidates, while building commercial alliances to both accelerate product development and generate shareholder value."

    Joining ImClone in 2003, Mr. O’Connor supported the clinical development, launch, and commercialization of ERBITUX(R). As ImClone’s senior vice president, general counsel, and secretary, he played a key role in resolving numerous issues facing ImClone, including extensive licensing negotiations, in advance of the company being sold to Eli Lilly in 2008.

    Just saying this doesn't really sound like he was surprised ImClone got bought out...

    Sentiment: Strong Buy

 
CYCC
0.70+0.01(+1.45%)Dec 26 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Virgin America Inc.
NASDAQFri, Dec 26, 2014 4:00 PM EST
TASER International Inc.
NASDAQFri, Dec 26, 2014 4:00 PM EST
The GEO Group, Inc.
NYSEFri, Dec 26, 2014 4:03 PM EST